Oxolife, member of CataloniaBio & HealthTech, announces it has appointed globally renowned fertility experts to its Scientific Advisory Board (SAB). The company is a biotechnology company specialized in improving embryo implantation in women undergoing fertility treatments with Assisted Reproduction Techniques (ART).
There is a very large and growing global infertility market, with 76m women a year affected – approximately 2% of the global female population. With approximately three million assisted reproductive technology cycles each year, of which 50% fail, there is a significant unmet medical problem. More than 30% of procedures fail due to implantation issues, the causes of which are largely unknown, and for which there are no treatment options.
Oxolife is developing a novel, easy to administer, non-hormonal, oral pill that boosts endometrial adhesion and invasion of the embryo, a major factor in improving pregnancy success rates. The SAB includes world leading experts in the fertility field who are involved in the clinical management at some of the top global reproductive clinics and research centers. They have a track record of nearly 1,200 fertility and reproduction-related publications. The SAB will be instrumental in advancing the development of OXO-001.
Juan García-Velasco, Chief Scientific Officer of IVIRMA and Chair of the Scientific Advisory Board of Oxolife, commented: “Millions of women undergo assisted reproductive technology cycles each year, with many of these cycles failing, and with no treatment options, it can be a very challenging time. We are very pleased to support the development of this innovative therapy which offers the potential to help millions of women worldwide conceive.
Agnès Arbat, Chief Executive Officer and Chief Medical Officer of Oxolife said: “Oxolife’s vision is to develop the first treatment that improves embryo implantation, a major factor in improving pregnancy success rates for women undergoing Assisted Reproductive Technology treatment. The experience and track record of this leading international Scientific Advisory Board will be invaluable in supporting our plans to accelerate the development of OXO-001.”
Comments